Diagonal Therapeutics
Diagonal Therapeutics Raises $125M Series B | Antibody Therapeutics
Diagonal Therapeutics Closes $125M Series B
Diagonal Therapeutics, developing disease-modifying clustering antibodies for rare genetic diseases, has raised $125 million in Series B funding.
The round was led by Sanofi Ventures and Janus Henderson Investors.
Key Highlights
- Focus on rare genetic diseases
- Novel antibody platform
- Strategic pharma backing from Sanofi
Company Overview
Diagonal Therapeutics is pioneering a new class of therapeutics using clustering antibodies to address rare genetic diseases with high unmet medical need.
Company Info
Investors (2)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free